Improving Adherence and Intensification of Medications Among Diabetes Patients
Improving Adherence and Intensification of Medications Among Diabetes Patients
批准号:
7657291
负责人:
EVE A KERR
金额:
$55.44万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-08-01 至 2011-07-31
关键词:
AddressAdherenceAlgorithmsBehavioralBlood PressureCaringClinicalClinical DataClinical ManagementClinical PharmacistsComplications of Diabetes MellitusCounselingDecision MakingDiabetes MellitusEffectiveness of InterventionsElectronicsElementsFailureGlucoseGoalsHealth systemHealthcareHyperglycemiaInformation SystemsInformation TechnologyInstitute of Medicine (U.S.)InterventionLipidsMeasuresOutcomePatientsPatternPharmaceutical PreparationsPharmacistsPharmacy facilityPrimary Health CareProcessProviderRandomized Controlled TrialsRiskRisk FactorsSiteSystemTechniquesTimeTrainingTranslationsTreatment ProtocolsVeteransWorkbaseblood pressure regulationcholesterol controlcompliance behaviorcomputerizedcost effectivenessdesigndiabetes riskeffective interventionelectronic datahealth administrationimprovedintervention effectmedication compliancemotivational enhancement therapypreventsatisfactionskillstranslational studytreatment adherencetreatment as usual
中文摘要
描述(由申请人提供):良好的血压(BP)、血糖和血脂控制对于预防糖尿病并发症至关重要,但很难实现。血压控制可能是最困难的目标,更多的糖尿病患者血压控制不佳,而不是血糖或血脂控制不佳。患者对药物的依从性差和临床医生未能开始或加强药物治疗都有助于对这些糖尿病风险因素的控制。我们建议评估一个量身定制的临床药师为基础的干预措施,以改善高血压糖尿病患者的糖尿病风险因素控制与药物依从性差或药物强化不足的两个综合交付卫生系统:凯撒永久和退伍军人健康管理局。本多中心、随机、对照试验的具体目的是:1)评价干预对血压、血糖和血脂控制的影响; 2)评估干预对患者血压、降糖和降脂方案依从性、这些方案的强度和对医疗保健的满意度的影响; 3)评价干预措施与常规护理相比的成本效益; 4)评价VA和Kaiser研究中心实施干预措施的过程,以确定可能与干预措施普遍性相关的研究中心之间的相似性和差异性。
使用电子数据,我们将主动识别8个初级保健干预团队中血压控制不佳、再灌注依从性差或药物强化不足的所有糖尿病患者; 8个非干预(对照)团队中的提供者也将被通知控制不佳的患者,并收到他们的依从性/强化信息。如果这些风险因素中的任何一个控制不佳,还将评估血糖和血脂的依从性和治疗强化模式。接受过动机访谈(MI)技术培训并在计算机化依从性模块指导下的临床药师将识别BP药物和(如适用)降糖和血脂药物的药物依从性障碍,并提供依从性咨询。他们还将被授权按照研究中心特定的算法改变和滴定药物。结果将在12个月后进行测量,届时将有多达2000名患者接受干预。在研究结束时,我们将准备一个翻译工具包,以加强干预措施的传播。这项转化研究旨在解决医学研究所的挑战,通过系统重新设计来提高质量,通过使用信息技术来识别有风险的患者,将临床药剂师整合到基于团队的护理中以支持临床决策,并为这些药剂师提供有效的行为咨询和药物改变所需的技能。在借鉴以前有效的干预措施的同时,这是第一项将这些基本要素结合联合收割机以改善糖尿病患者结局的研究。良好的血压(BP),葡萄糖和胆固醇控制对于预防糖尿病并发症至关重要,但很难实现。患者对药物的依从性差和临床医生未能开始或加强药物治疗都有助于对这些糖尿病风险因素的控制。这项转化研究旨在解决医学研究所的挑战,通过系统重新设计来提高质量,通过使用信息技术来识别可能需要更具体帮助的患者,将临床药剂师整合到基于团队的护理中以支持有效的临床管理,并为这些药剂师提供帮助患者管理自己的药物所需的技能。在借鉴以前有效的干预措施的同时,这是第一项将这些基本要素结合联合收割机以改善糖尿病患者结局的研究。
英文摘要
DESCRIPTION (provided by applicant): Good blood pressure (BP), glycemic, and lipid control is essential to prevent complications of diabetes mellitus but is very difficult to achieve. BP control may be the most difficult goal, with more diabetes patients having poor BP control than poor glycemic or lipid control. Both poor patient adherence to medications and clinicians' failure to initiate or intensify medications contribute to poor control of these diabetes risk factors. We propose to evaluate a tailored clinical pharmacist-based intervention to improve diabetes risk factor control among hypertensive diabetes patients with poor medication adherence or inadequate medication intensification in two integrated delivery health systems: Kaiser Permanente and the Veterans Health Administration. The Specific Aims of this multi-site, cluster randomized, controlled trial are: 1)To evaluate the effects of the intervention on BP, glycemic, and lipid control; 2)To assess the impact of the intervention on patients' adherence to BP, anti-hyperglycemic, and lipid-lowering regimens, intensity of these regimens, and satisfaction with health care; 3) To evaluate the cost-effectiveness of the intervention compared to usual care; and 4) To evaluate the process of intervention implementation in VA and Kaiser sites in order to identify similarities and differences across sites that may relate to intervention generalizability.
Using electronic data, we will proactively identify all diabetes patients within each of 8 primary care intervention teams who have poor BP control and either poor refill adherence or insufficient medication intensification; providers in the 8 non-intervention (control) teams will also be notified of patients with poor control and receive their adherence/intensification information. Adherence and treatment intensification patterns will also be evaluated for glycemia and lipids if either of these risk factors is poorly controlled. Clinical pharmacists, trained in motivational interviewing (MI) techniques and guided by computerized adherence modules, will identify barriers to medication adherence for BP medications and (as appropriate) for anti-hyperglycemic and lipid medications and provide adherence counseling. They will also be authorized to change and titrate medications following site-specific algorithms. Outcomes will be measured after 12-months, at which time up to 2000 patients will have received the intervention. At the conclusion of the study, we will prepare a translation toolkit to enhance dissemination of the intervention. This translational study is designed to address the Institute of Medicine challenge to improve quality through system redesign by using information technology to identify patients at risk, integrating clinical pharmacists in team-based care to support clinical decision making, and providing those pharmacists with the skills necessary to deliver effective behavioral counseling and medication change. While drawing on previously effective interventions, this is the first study to combine these essential elements to improve outcomes for patients with diabetes. Good blood pressure (BP), glucose, and cholesterol control is essential to prevent complications of diabetes mellitus but is very difficult to achieve. Both poor patient adherence to medications and clinicians' failure to initiate or intensify medications contribute to poor control of these diabetes risk factors. This translational study is designed to address the Institute of Medicine challenge to improve quality through system redesign by using information technology to identify patients who may need more specific help, integrating clinical pharmacists in team-based care to support effective clinical management, and providing those pharmacists with the skills necessary to help patients manage their own medications. While drawing on previously effective interventions, this is the first study to combine these essential elements to improve outcomes for patients with diabetes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Integrating Systems of VA and non-VA Care Delivery in the Evolving VA Community Care Network
-
批准号:9832972
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:EVE A KERR
-
依托单位:
Center for Clinical Management Research (CCMR)
-
批准号:9076153
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:EVE A KERR
-
依托单位:
Improving Adherence and Intensification of Medications Among Diabetes Patients
-
批准号:7314286
-
项目类别:
-
资助金额:$57.65万
-
财政年份:2007
-
负责人:EVE A KERR
-
依托单位:
Improving Adherence and Intensification of Medications Among Diabetes Patients
-
批准号:7477189
-
项目类别:
-
资助金额:$56.61万
-
财政年份:2007
-
负责人:EVE A KERR
-
依托单位:
Improving Adherence and Intensification of Medications Among Diabetes Patients
-
批准号:7904800
-
项目类别:
-
资助金额:$41.56万
-
财政年份:2007
-
负责人:EVE A KERR
-
依托单位:
Conference on Assessing Quality of Care for Diabetes
-
批准号:7059266
-
项目类别:
-
资助金额:$1.0万
-
财政年份:2005
-
负责人:EVE A KERR
-
依托单位:
海外基金